🇺🇸·1d agoIndustry
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
HyBryte™ demonstrates more rapid and robust treatment response compared to Valchlor® during 12-week...
Publisher
S
Soligenix
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
HyBryte™ demonstrates more rapid and robust treatment response compared to Valchlor® during 12-week...
Source route
Continue on ir.soligenix.com
Leave the platform to read the original full article on the publisher site.
Source: Soligenix
Scope: Industry
Related coverage
More related coverage
Regeneron News·1d ago
Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
Regeneron News·1d ago
EYLEA HD®(aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)
Genmab·2d ago
transactions shares and linked securities genmab made 77
Genmab·2d ago